|
|
Monthly dose of PCSK9 inhibitor lowers serum cholesterol |
|
Reuters: An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. The drug, alirocumab, belongs to an emerging class of injectable drugs that block a naturally occurring protein called PCSK9, which inhibits the liver from expelling "bad" LDL cholesterol.
|
|
|
Ibuprofen extends lifespan in yeast., worms, and fruit flies. |
|
Huffington Post: Ibuprofen, a common over-the-counter drug used to relieve pain and fever, could hold the key to a longer, healthier life, according to a study conducted by the Buck Institute for Research on Aging. The study, published in the December edition of PLoS Genetics, found that regular doses of ibuprofen extended the lifespan of yeast, worms and fruit flies.
|
|
Ultrasonography for nephrologists course Jan 10-11, 2015 |
|
This is a CME-accredited, comprehensive two-day training course that includes both didactic and practical training. It covers all aspects of ultrasonography for nephrologists, including: Diagnostic imaging of native kidneys and allografts; Percutaneous biopsy of native kidneys and allografts; End-stage kidneys, bladder, ultrasound guidance for venous access; Coding, billing, reporting, and equipment. No prior training or experience required. For questions, please read the frequently asked questions section below before contacting us.
|
|
JAMA: New hyperkalemia sorbent effective in reducing hyperkalemia |
|
JAMA: Conclusions and Relevance Among outpatients with hyperkalemia, open-label sodium zirconium cyclosilicate reduced serum potassium to normal levels within 48 hours; compared with placebo, all 3 doses of zirconium cyclosilicate resulted in lower potassium levels and a higher proportion of patients with normal potassium levels for up to 28 days. Further studies are needed to evaluate the efficacy and safety of zirconium cyclosilicate beyond 4 weeks and to assess long-term clinical outcomes.
|
|
Fiber supplementation lower p-cresol levels |
|
JREN in press: Results: Plasma p-cresol decreased from 7.25 ± 1.74 mg/L during week 1 to 5.82 ± 1.72 mg/L during week 12 (P < .05), and in participants with high compliance (>70% inulin intake), from 6.71 ± 1.98 mg/L to 4.22 ± 1.16 mg/L (P < .05). Total fiber intake increased from 16.6 ± 1.7 g/day during control to 26.5 ± 2.4 g/day (P < .0001) with the added pea hull and to 34.5 ± 2.2 g/day with pea hull and inulin (P < .0001). Stool frequency increased from 1.4 ± 0.2 stools/day during control to 1.9 ± 0.3 stools/day during both fiber periods (P < .05). No change in overall QoL was observed. Conclusions: Supplementing the diet of CKD patients with fiber may be a dietary therapy to reduce p-cresol and improve stool frequency.
|
|
|
|
|
<< Start < Prev 221 222 223 224 225 226 227 228 229 230 Next > End >>
|
|
Page 223 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
